Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | RHEB | Q15382 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583616 | 0.84 | GRM5 (0.48) | GRM5VCAM1MEN1KMT2A | |
| SCHEMBL11620108 | 0.84 | GRM5 (0.41) | GRM5VCAM1 | |
| SCHEMBL13045682 | 0.84 | GRM5 (0.41) | GRM5VCAM1TTRALBMEN1 | |
| SCHEMBL10379441 | 0.80 | ALDH1A1 (0.41) | GRM5VCAM1MEN1KMT2AGPR35 | |
| SCHEMBL30824106 | 0.79 | GRM5 (0.38) | GRM5VCAM1TTRALBMEN1 | |
| SCHEMBL11296944 | 0.79 | GRM5 (0.51) | GRM5VCAM1 | |
| SCHEMBL6177216 | 0.79 | GRM5 (0.38) | GRM5VCAM1TTRALBMEN1 | |
| SCHEMBL30563178 | 0.79 | GRM5 (0.38) | GRM5VCAM1 | |
| SCHEMBL30745049 | 0.79 | MEN1 (0.41) | GRM5VCAM1TTRALBMEN1 | |
| SCHEMBL1335200 | 0.79 | GRM5 (0.38) | GRM5VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053805-B | Preparation method of thiazine feed additive | 广州市兴达动物药业有限公司 | 2020-12-18 | — | — | CN | claimed |
| CN-111151248-A | Method for catalyzing heterocyclic halogen-containing organic matter hydrogenation dehalogenation by using supported metal oxide | 浙江大学 | 2020-05-15 | — | — | CN | claimed |
| EP-4747258-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4735423-A1 | KV7 MODULATORS | Saniona A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | MERCK SHARP & DOHME LLC | 2026-03-03 | — | — | US | disclosed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4643954-A2 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-11-05 | — | — | EP | disclosed |
| US-12459932-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4630404-A1 | UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| EP-4630406-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| EP-0603299-A1 | SEMI-PERMEABLE MEMBRANES DERIVED FROM REACTIVE OLIGOMERS | THE DOW CHEMICAL COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993005866-A1 | SEMI-PERMEABLE MEMBRANES DERIVED FROM REACTIVE OLIGOMERS | THE DOW CHEMICAL COMPANY (US) | 1993-04-01 | — | — | WO | disclosed |
| US-5156656-A | Gas separation | THE DOW CHEMICAL COMPANY (US) | 1992-10-20 | — | — | US | disclosed |
| US-4999432-A | Heating and dechlorination of a chloropyridine | DOWELANCO (US) | 1991-03-12 | — | — | US | disclosed |
| EP-0415498-A2 | Fluorination with hydrogen fluoride | DOWELANCO (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0210648-B1 | 5-CHLORO-S-TRIAZOLO/4,3-A/PYRIDINE-7-CARBOXYLIC ACIDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-11-28 | — | — | EP | disclosed |
| US-4814456-A | Chlorinating waste streams to recover cyanopyridine contained therein | THE DOW CHEMICAL COMPANY (US) | 1989-03-21 | — | — | US | disclosed |
| US-4650872-A | 5-chloro-s-triazolo[4,3-a]-pyridine-7-carboxylic acids, useful as antiallergic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0210648-A1 | 5-chloro-s-triazolo/4,3-a/pyridine-7-carboxylic acids | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459932-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | GRM5 3672/4885VCAM1 4093/4885TTR 4498/4885 |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | NHERF1, ZC3HAV1, SARS1 | GRM5 3963/4885VCAM1 2086/4885TTR 1091/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | GRM5 380/4885VCAM1 1203/4885TTR 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.